乐
乐观
乐观 · 25%TAK
$18.07
情景价格
$19.450
+0.449 (+2.31%)收盘时
Loading chart…
- 最高
- 19.890
- 开盘
- 19.580
- 成交量加权均价
- 19.60
- 成交量
- 4.39M
- 市值
- 40.51B
- 最低
- 19.450
- 成交额
- 85.98M
- 企业价值/息税折旧摊销前利润（TTM）
- 3.05
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
AI 分析 of Takeda Pharmaceutical Co Ltd (TAK)
买入Takeda Pharmaceutical Co Ltd (TAK) appears to be a good buy right now due to its current price of 18.73, which is above the 200-day simple moving average of 17.25, suggesting a bullish trend. Additionally, the stock has shown a strong year-to-date change of +19.91% and a one-year change of +36.52%, indicating solid performance. The RSI of 67.41 suggests that the stock is nearing overbought conditions but still has room for growth. The main risk is the negative net income reported in Q4 2026, which was -368.47 billion JPY, highlighting potential volatility in earnings.
估值指标
Takeda Pharmaceutical Co Ltd（TAK）当前预期市盈率为 11.47，5 年平均预期市盈率为 25.24。
Alphio AI 对 TAK 的价格情景
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。
事件时间线
资讯
5.010-15NewsfilterORZEYFUL Approved for Launch in Japan and China
- 9.009-30Newsfilter
Zasocitinib Shows Superiority in Psoriasis Treatment
- 9.009-22Newsfilter
Takeda Unveils New Data at ESMO Congress on Cancer Treatments
- 8.509-18Newsfilter
Takeda Awards $22.2 Million to 2026 Global CSR Partners
- 8.509-14Newsfilter
Takeda's Zasocitinib Receives FDA Priority Review for Psoriasis
TAK 常见问题 —— 由 Alphio AI 解答
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies. It operates in the Healthcare sector.
Takeda Pharmaceutical Co Ltd (TAK) appears to be a good buy right now due to its current price of 18.73, which is above the 200-day simple moving average of 17.25, suggesting a bullish trend. Additionally, the stock has shown a strong year-to-date change of +19.91% and a one-year change of +36.52%, indicating solid performance. The RSI of 67.41 suggests that the stock is nearing overbought conditions but still has room for growth. The main risk is the negative net income reported in Q4 2026, which was -368.47 billion JPY, highlighting potential volatility in earnings.
社区
更多 ↗暂无帖子
注册或登录后参与讨论本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。